Inhibiting METTL3 in macrophages alleviates colitis by enhancing M2 polarization via upregulating IRAKM

Key Points

• Inhibiting METTL3 results in significant alleviation of colitis symptoms, indicating a potential therapeutic target.
• Key evidence shows that M2 polarization increases alongside IRAKM levels in treated macrophages, confirming positive outcomes.
• Assessment using macrophage cell line analysis demonstrates how METTL3 inhibition can modulate immune responses to alleviate inflammation.
• Highlights the potential for targeting METTL3 to regulate macrophage polarization and improve colitis outcomes, but further studies are needed.